Tag: AstraZeneca Plc (AZN)

AstraZeneca: Tagrisso Recommended for Marketing Authorization in the EU for Early Stage EGFRm NSCLC

AstraZeneca: Tagrisso for Adult Patients with Early-Stage EGFRm NSCLC... AstraZeneca (AZN): Tagrisso (osimertinib) has been recommended for marketing authorization in the European Union for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

CureVac N.V.

Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about the German firm, CureVac N.V. (CVAC), when the company announced business updates and financial results for its fourth quarter and full-year 2020. The reason for our interest was the fact that the U.S. was looking to take over this firm two years ago to no avail. A more important …

A Flashback and Future Projections

Prohost Letter #445 A Flashback and Future Projections 1. A Follow-Up on Recently Posted News from ProhostBiotech 2. Answering Questions 3. Development-Stage Firms to Outperform 4. Oversold Revenue-Generating Firms 5. Tables with FAIR 2021 Targets for the Prohost Selected Firms In This Issue We Discuss the Following Firms: Anixa Biosciences (

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.  

AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19  AstraZeneca (AZN) has modified an existing agreement with the U.S. Government to supply up to 500,000 additional doses of AZD7442 - a long-acting antibody (LAAB) combination in late-stage development, for the prevention and treatment of COVID-19. We stress . . . This content is for paid subscribers. Please click here to subscribe or here to …

Prohost Letter #444

Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predicting the pandemic, which continues to plague the world. As 2021 approached, we were unable to the End of the Year issue on time as we lacked the information required for the fair …

Compugen: Why the Great Expectations from this Firm

The Compugen Story For those who are still asking about the value of Compugen’s (CGEN) discoveries our answer is that the best story written about this firm is its own autobiography.   We believe Compugen's accomplishments are extremely valuable in improving the treatment of cancers. As small as the firm is, Compugen . . . This content is for paid subscribers. Please click here to subscribe …

Compugen: More Highlighted News

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen (CGEN) and AstraZeneca (AZN) entered into . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Acquisitions that Make Sense

Acquisitions  AstraZeneca Acquires Alexion Pharmaceuticals AstraZeneca (AZN) and Alexion Pharmaceuticals (ALXN) entered into a definitive agreement for . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

A New COVID-19 Vaccine is Showing Successful Results. See Also: More Details About the Effective COVID-19 Vaccines

COVID-19 Vaccine Updates Pfizer’s (PFE)/BioNTech’s (BNTX) and Moderna’s (MRNA) COVID-19 vaccines have demonstrated safety at around 95% efficacy.   AstraZeneca (AZN) and Oxford University announced today that their COVID-19 vaccine was 90% effective in preventing infections. The efficacy average, however, was 70%, leading the stock to travel south rather than north.     Regardless of the efficacy differences AstraZeneca stated that it would immediately prepare …

Moderna’s Future Growth

Moderna Inc COVID-19 Vaccine Candidate Moderna Inc (MRNA) announced the completion of the case accrual for the first interim analysis of Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate. The firm announced a significant increase in the rate of case identification across sites in the last week. As a result, the Company expects the first interim analysis will include substantially more than 53 …

Tracking the News from AstraZeneca About Experimental Vaccine, AZD1222, for COVID-19

News from AstraZeneca About COVID-19 Vaccine, AZD1222 From AstraZeneca (AZN) we learned that its COVID-19 vaccine, AZD1222, which is being developed in collaboration with Oxford University, has produced a similar immune response in older and younger adults. A spokesman from the firm stated that the results have further built the body of evidence for the safety and immunogenicity of AZD1222. On October 23, 2020 AstraZeneca’s …

We Continue to Track the COVID-19 Vaccines. See Also: CRISPR Therapeutics Immuno-Oncology Results are Good.

The Latest on the COVID-19 Vaccines AstraZeneca (AZN): After pausing for more than a month, AZN is expected to resume its Phase 3 US study of its COVID-19 vaccine. The trial was paused after a patient, who received the vaccine, developed an illness suspected to be a serious spinal inflammatory condition known as transverse myelitis. The patient was . . . This content is for …

Gilead Sciences Could Acquire Immunomedics at $20 Billion. See Also: AstraZeneca Vaccine Trial Resumed

Gilead Sciences News Is Not Just Gossip Real news, not just gossip, is spreading today about Gilead Sciences (GILD) nearing a deal to acquire the biotech firm Immunomedics (IMMU) for $20 billion. Immunomedics current market value is around $10 billion which means that Gilead is buying it at double its value. The deal could be announced on Monday, if not sooner, if the talks go …

The Small Firm Whose Stock Soared in Yesterday’s Market

Firms' with COVID-19 Vaccines Stock Performance A look at the stock performance of the COVID-19 vaccine firms that have demonstrated early, promising and even good news regarding their prophylactic effect. The outcome was as follows:    Moderna (MRNA): was down over 12% after an analyst at J.P.Morgan downgraded the company to neutral from overweight, overvaluation . . . This content is for paid subscribers. Please …

A Potential Merger Between AstraZeneca Plc and Gilead Sciences?

AstraZeneca Plc and Gilead Sciences Potential Merger News spread through the media announcing that AstraZeneca Plc (AZN) has approached Gilead Sciences (GILD) regarding a possible, potential merger. People familiar with the subject (we don’t know who they are) believe that such a merger, if it materializes, would be the highest healthcare business deal on record. As told, the story recounts that AstraZeneca got in touch …

Questions & Answers

The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for the CytomX stock selloff that occurred in early May? In order to answer this question we need to explain CytomX’s (CTMX) Probody therapeutics. These novel treatments are designed to remain inactive until they are activated only . . . This content is for paid subscribers. Please click here to subscribe …
Prohost Letter #439

Prohost Letter #439

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known as COVID-19) outbreak would affect not only people’s health and survival but the world’s economy, Wall Street’s performance, and especially the international giant industrial firms that are committed to China. British AstraZeneca (AZN